Indonesia antirheumatic drugs market was valued at US$3,260.272 million in 2019. The market for antirheumatic drugs in Indonesia is projected to witness a healthy CAGR throughout the forecast period primarily on account of the high incidence of malaria throughout the country along with the moderate prevalence of numerous rheumatic diseases such as osteoarthritis and rheumatoid arthritis among others. According to the World Health Organization, the prevalence of osteoarthritis at the age of 61 in Indonesia was around 5% during the year 2015. Furthermore, the exponential growth of the geriatric population of the country is also bolstering the growing demand for numerous types of antirheumatic drugs throughout the country, thus positively impacting the market growth during the next five years. For instance, the population ages 65 and above in the country reached 15,677,491 by 2018 from 11,661,484 in 2008 (Source: The World Bank Group).
Furthermore, malaria is considered a serious health problem in the country. Socio-demographic factors are considered to be highly responsible for the high impact of malaria throughout the country. Also, according to the data from the World Health Organization, in 2017, the reported confirmed cases of malaria in the health facilities across the country were around 261,617. Also, the division of the population on the basis of high transmission (>1 case per 1000 population) was around 16.9 million and low transmission (>1 case per 1000 population) was evaluated around 247.1 million for the same period. Therefore, the high prevalence of malaria in Indonesia is also projected to be one of the key factors supplementing the antirheumatic drugs market growth in the country over the course of the next five years.
Indonesia antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Indonesia antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).